Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes

OBJECTIVE: Glucagon receptor (GCGR) blockage improves glycemic control and increases circulating glucagon-like peptide-1 (GLP-1) level in diabetic animals and humans. The elevated GLP-1 has been reported to be involved in the hypoglycemic effect of GCGR blockage. However, the source of this elevatio...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMJ Open Diabetes Res Care
Autors principals: Lang, Shan, Yang, Jin, Yang, Kun, Gu, Liangbiao, Cui, Xiaona, Wei, Tianjiao, Liu, Junling, Le, Yunyi, Wang, Haining, Wei, Rui, Hong, Tianpei
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Emerging Technologies, Pharmacology and Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7059498/
https://ncbi.nlm.nih.gov/pubmed/32139602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjdrc-2019-001025
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars